Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12409–12414 | Cite as

Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy

  • Xin Fu Liu
  • Hui Zhang
  • Jian Qun Sun
  • Chan Yin
  • Teng Fei Liu
  • Hua Yang
  • Long Hua Chen
Research Article

Abstract

Thymidylate synthase (TS) is a prognostic marker in various tumors. However, the results of previous investigations in gastric cancer (GC) were controversial. The objective of this article is to investigate whether TS expression is associated with clinical outcome in advanced GC receiving capecitabine alone chemotherapy. The study reviewed 58 cases of advanced GC in patients aged ≥65 years between December 2008 and June 2012. All patients were treated with capecitabine alone chemotherapy. Immunohistochemical staining for TS protein expression was performed. The relationships between TS expression and clinicopathological characteristics (included age, gender, number of metastatic sites, Eastern Cooperative Oncology Group (ECOG) score, differentiation, and lymph node metastatic status), chemotherapy response, progression-free survival (PFS), and overall survival (OS) were evaluated. There was no association between TS expression and age, gender, number of metastatic sites, ECOG score, differentiation, and lymph node metastatic status (P > 0.05). The chemotherapy response rates among patients with low- and high-level expression of TS protein were 52.0 % (13/25) and 21.2 % (7/33), respectively (χ 2 = 5.968, P = 0.015). The median PFS and OS in patients with low-level TS expression were significantly longer than those with high-level TS expression (PFS 8.0 vs 2.8 m, P = 0.001; OS 13.3 vs 7.9 m, P = 0.002, respectively). Multivariate Cox regression analysis revealed that TS expression was independent risk factor for OS (hazard ratio (HR) 0.237; 95 % confidence interval (CI) 0.108 to 0.520; P = 0.000). The present study demonstrates that TS expression is associated with chemotherapy response, PFS, and OS in advanced GC patients treated with capecitabine alone chemotherapy.

Keywords

Gastric neoplasm Thymidylate synthase Capecitabine Immunohistochemistry 

Abbreviations

TS

Thymidylate synthase

ECOG

Eastern Cooperative Oncology Group

GC

Gastric cancer

PFS

Progression-free survival

OS

Overall survival

IHC

Immunohistochemical

PCR

Polymerase chain reaction

Notes

Acknowledgments

We thank the staffs of the affiliated Nanfang Hospital of Southern Medical University for their help.

Funding support

The present study was supported by research grants from the Health Department of Hunan Province (no. B2011-138).

Conflicts of interest

None

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRefGoogle Scholar
  2. 2.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC. Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther. 2012;37(3):266–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, et al. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 2013;16(2):175–82.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22(12):2604–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Qiu MZ, Wei XL, Zhang DS, Jin Y, Zhou YX, Wang DS, et al. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol. 2014;35(5):4369–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22(3):529–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, et al. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012;12(5):404–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Gronberg BH, Lund-Iversen M, Strom EH, Brustugun OT, Scott H. Associations between TS, TTF-1, FR-alpha, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol. 2013;8(10):1255–64.PubMedCrossRefGoogle Scholar
  11. 11.
    van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, et al. Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. Eur J Surg Oncol. 2012;38(11):1058–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, et al. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol. 2010;102(5):503–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Koizumi W, Tanabe S, Azuma M, Ishido K, Nishimura K, Sasaki T, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010;126(1):162–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg. 2010;395(3):217–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers. 2011;16(1):74–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 2009;100(5):732–8.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2000;87(12):881–6.PubMedGoogle Scholar
  18. 18.
    Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, et al. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Cancer. 2013;119(2):454–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-Rayes BF, Kauh JS, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol. 2011;18(9):2699–705.PubMedCrossRefGoogle Scholar
  20. 20.
    Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013;8(1):19–30.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, et al. Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol. 2012;7(6):982–92.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, et al. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Int J Cancer. 2013;135(1):128–37.CrossRefGoogle Scholar
  23. 23.
    Donada M, Bonin S, Nardon E, De Pellegrin A, Decorti G, Stanta G. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol. 2011;137(2):201–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer. 2012;75(3):306–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Yokota K, Sasaki H, Okuda K, Shitara M, Hikosaka Y, Moriyama S, et al. Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma. Exp Ther Med. 2012;4(4):589–93.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Squires MHR, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, et al. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer. 2013;119(17):3242–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Mirza A, Brown M, McNulty C, Valentine J, Annesley A, Galloway S, et al. A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma. Gastroenterol Res Pract. 2013;2013:502153.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Kamoshida S, Matsuoka H, Ishikawa T, Maeda K, Shimomura R, Inada K, et al. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol. 2004;34(10):594–601.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Q, Shen J, Wang H, Hu J, Yu L, Xie L, et al. TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer. Cancer Chemother Pharmacol. 2014;73(2):325–33.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xin Fu Liu
    • 1
    • 2
  • Hui Zhang
    • 2
  • Jian Qun Sun
    • 2
  • Chan Yin
    • 2
  • Teng Fei Liu
    • 4
  • Hua Yang
    • 3
  • Long Hua Chen
    • 1
  1. 1.Department of Radiation Oncology, Nanfang HospitalSouthern Medical UniversityGuangzhouPeople’s Republic of China
  2. 2.Department of Oncology and HematologyShaoyang Central HospitalShaoyangPeople’s Republic of China
  3. 3.Department of PathologyShaoyang Central HospitalShaoyangPeople’s Republic of China
  4. 4.Department of Pathology, Nanfang HospitalSouthern Medical UniversityGuangzhouPeople’s Republic of China

Personalised recommendations